At RBV Capital, we are building a diversified portfolio of early-stage breakthrough assets.
Our investment strategy focuses on innovative science addressing critical unmet medical needs, and relies on selecting strong management teams with a clear vision.
We are interested in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, and medical device companies.
IAG’s Team published a new article ‘Artificial intelligence-based Clinical Decision Support systems using advanced medical imaging & Radiomics’, Elsevier’s Current Problems in Diagnostic Radiology, June 2020
ZiteLab Aps and IAG, Image Analysis Group Partner to Integrate IAG’s DYNAMIKA and the SAMRI Platforms to Advance Connectivity and Interoperability in Clinical Trials of Rheumatic Diseases
PIPE-505 is the first small molecule developed specifically for the treatment of sensorineural hearing loss (SNHL) associated with speech-in-noise impairment
